Global Depression Therapeutics Market By Overview
Depression is serious mood disorder characterized by persistent low mood and feeling of sadness and loss of interest. Accurate diagnosis of depression ensure further safe and effective treatment. Drug medication, psychotherapy or combination of both treatments is most preferred treatment modality in the management of depression. Antidepressants are medicines that treat depression. Antidepressants include diverse range of drug categories which mainly includes selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and serotonin receptor modulators (SRMs).
Global Depression Therapeutics Market By Drivers & Restraints
Growing cases of mental disorders including depression and anxiety owing to changing lifestyle, increasing work pressure, trauma, and genetic factors are factors restraining growth of the global depression therapeutics market.
Incresing numbers of clinical trial studies currently undergoing for the treatment of depression by various key players in the market, is expected to offer lucrative growth opportunities in near future. For instance, in December 2017, Sage Therapeutics: a clinical –stage biopharmaceutical company developing the novel medicines for the treatment of central nervous system (CNS) disorders reports positive result from its phase II clinical trial of SAGE-217 in the treatment of patients with moderate to severe major depression disorder (MDD).
Global Depression Therapeutics Market By Segmentations & Regional Insights
The global depression therapeutics market has been segmented on the basis of drug type, distribution channel, and region.
On the basis of drug type, depression therapeutics market is segmented into Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), and others. Distribution channel of depression therapeutics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, andAfrica.
Global Depression Therapeutics Market By Competitive Landscape & Key Players
The key players operating in the global depression therapeutics market includes Pfizer, Inc., Eli Lilly and Company, AstraZeneca Plc, Allergan Plc, GlaxoSmithKline Plc, Intellipharmaceutics International, Inc., Takeda Pharmaceutical Company Limited, H.Lundbeck A/S, Otsuka Holdings Co.,Ltd., Apotex, Inc., Shionogi & Co. Ltd., Zhejiang Hua Hai Pharmaceutical Co., Ltd., and Chengdu Kanghong Pharmaceutical Group Co.,Ltd.
FAQs
Global Depression Therapeutics Market is segmented By Drug Type (Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), and Others), and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
Growing cases of mental disorders including depression and anxiety owing to changing lifestyle, increasing work pressure, trauma, and genetic factors are factors restraining growth of the global depression therapeutics market.
Depression Therapeutics Market accounted for US$ 13.7 billion in 2020 and is estimated to be US$ 17.49 billion by 2030 and is anticipated to register a CAGR of 3.0%.
Depression Therapeutics Market is segmented by Drug type, Distribution, and region.
the development of novel therapeutic approaches, increasing research in gene therapy, and advancements in precision medicine, presenting significant opportunities in the global Sandhoff Disease Treatment Market.
the need for effective treatments for rare genetic disorders, advancements in medical research, increasing awareness and diagnosis of Sandhoff disease, and collaborations between pharmaceutical companies and research institutions.
North America, Europe, and Asia-Pacific are likely to be key regions, but the situation is dynamic, and it's advisable to refer to the latest reports for the most current information.
The key players operating in the global depression therapeutics market includes Pfizer, Inc., Eli Lilly and Company, AstraZeneca Plc, Allergan Plc, GlaxoSmithKline Plc, Intellipharmaceutics International, Inc., Takeda Pharmaceutical Company Limited, H.Lundbeck A/S, Otsuka Holdings Co.,Ltd., Apotex, Inc., Shionogi & Co. Ltd., Zhejiang Hua Hai Pharmaceutical Co., Ltd., and Chengdu Kanghong Pharmaceutical Group Co.,Ltd.